NEW YORK, August 6, 2026
MiNK Therapeutics announced that it will report its second-quarter 2026 financial results before U.S. markets open on August 13, 2026, while also providing a comprehensive clinical and corporate update centered on agenT-797, the company’s investigational off-the-shelf allogeneic invariant natural killer T (iNKT) cell therapy. During the scheduled conference call and webcast, management plans to present new clinical data evaluating agenT-797 in patients with acute pulmonary injury, alongside important business developments supporting the continued advancement of its cell therapy pipeline. The company stated that the presentation will highlight recent progress in clinical development while outlining strategic initiatives aimed at expanding patient access through the launch of a named-patient program.
AgenT-797 Continues Advancement Across Multiple Clinical Programs
AgenT-797 is MiNK Therapeutics’ lead investigational allogeneic iNKT cell therapy, developed as an off-the-shelf, cryopreserved cellular immunotherapy designed to rapidly restore immune balance without requiring patient-specific manufacturing. The therapy is currently being investigated across several clinical indications, including solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure, where immune dysfunction contributes to severe disease progression. The upcoming corporate update is expected to include new clinical observations from patients with pulmonary injury, providing additional insight into the therapy’s potential role in treating acute lung conditions. Company executives are also expected to discuss the newly launched named-patient access program, which may expand availability of the investigational therapy under applicable regulatory pathways while additional clinical development continues.
iNKT Cell Platform Designed to Restore Immune Function
MiNK Therapeutics is pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies, a unique class of immune cells that bridge innate and adaptive immunity to generate rapid and durable immune responses. Unlike conventional autologous cell therapies, MiNK’s platform utilizes healthy donor-derived cells manufactured at scale, allowing treatment to be available off the shelf without individualized production timelines. Beyond agenT-797, the company is advancing additional TCR-based and neoantigen-targeted iNKT programs intended to provide tissue-specific immune activation across cancer, autoimmune diseases, and immune-mediated disorders. By combining scalable manufacturing with broad therapeutic applicability, MiNK aims to establish a new generation of immune reconstitution therapies capable of improving accessibility and treatment outcomes for patients with serious diseases.
Advertisement
Upcoming Corporate Update Expected to Highlight Clinical and Business Milestones
The August 13, 2026 webcast will provide investors and the medical community with updates on clinical progress, operational developments, and financial performance during the second quarter of 2026. Management is expected to discuss the latest findings supporting agenT-797’s development in acute lung injury, ongoing clinical activities across additional therapeutic indications, and recent business initiatives designed to strengthen the company’s development strategy. As MiNK continues expanding its iNKT cell therapy platform, the upcoming presentation is anticipated to offer important insight into future clinical milestones and the company’s plans to advance its innovative immunotherapy pipeline toward broader clinical application.
Source:MiNK Therapeutics, press release
